Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 7, 2010, Pages 2370-2374

  Lee Dutra, Alice ^a   Wiener, Danielle K ^a   Arienti, Kristen L ^a   Liu, Jing ^a   Mani, Neelakandha ^a   Ameriks, Michael K ^a   Axe, Frank U ^a   Gebauer, Damara ^a   Desai, Pragnya J ^a   Nguyen, Steven ^a   Randal, Mike ^b   Thurmond, Robin L ^a   Sun, Siquan ^a   Karlsson, Lars ^a   Edwards, James P ^a   Jones, Todd K ^a   Grice, Cheryl A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Cathepsin; Protease; Thioether

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PYRAZOLE DERIVATIVE; SULFIDE;

ARTICLE; BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CATHEPSINS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEASE INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES;

EID: 77949486207     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.108     Document Type: Article

References (14)

1. Gupta S., Kumar Singh R., Dastidar S., and Ray A. Exp. Opin. Ther. Targets 12 (2008) 291
2. Villandangos J.A., Bryant R.A.R., Deussing J., Driessen C., Lennon-Dumenil A.-M., Riese R.J., Roth W., Saftig P., Shi G.-P., Chapman H.A., Peters C., and Ploegh H.L. Immunol. Rev. 172 (1999) 109
3. Nakagawa T.Y., and Rudensky A.Y. Immunol. Rev. 172 (1999) 121
4. Shi G.-P., Villadangos J.A., Dranoff G., Small C., Gu L., Haley K.J., Riese R., Ploegh H.L., and Chapman H.A. Immunity 10 (1999) 197
5. Thurmond R.L., Beavers M.P., Cai H., Meduna S.P., Gustin D.J., Sun S., Almond H.J., Karlsson L., and Edwards J.P. J. Med. Chem. 47 (2004) 4799
6. Thurmond R.L., Sun S., Sehon C.A., Baker S.M., Cai H., Gu Y., Jiang W., Riley J.P., Williams K.N., Edwards J.P., and Karlsson L. J. Pharm. Exp. Ther. 308 (2004) 268
7. Gustin D.J., Sehon C.A., Wei J., Cai H., Meduna S.P., Khatuya H., Sun S., Gu Y., Jiang W., Thurmond R.L., Karlsson L., and Edwards J.P. Bioorg. Med. Chem. Lett. 15 (2005) 1687
8. Grice C.A., Tays K., Khatuya H., Gustin D.J., Butler C.R., Wei J., Sehon C.A., Sun S., Gu Y., Jiang W., Thurmond R.L., Karlsson L., and Edwards J.P. Bioorg. Med. Chem. Lett. 16 (2006) 2209
9. Wei J., Pio B.A., Cai H., Meduna S.P., Sun S., Gu Y., Jiang W., Thurmond R.L., Karlsson L., and Edwards J.P. Bioorg. Med. Chem. Lett. 17 (2007) 5525
10. Ameriks M.A., Axe F., Edwards J.P., Gu Y., Karlsson L., Randal M., Sun S., Thurmond R.L., and Zhu J. Bioorg. Med. Chem. Lett. 19 (2009) 6131
11. Ciattini P.G., Morera E., and Ortar G. Tetrahedron Lett. 36 (1995) 4133
12. Bates C.G., Gujadhur R.K., and Venkataraman D. Org. Lett. 4 (2002) 2803
13. The crystal structure of compound 13 could not be uploaded into the PDB because structure factors were not provided by Sunesis Pharmaceuticals, presumably because they were not required for submission into the PDB at the time this structure was solved (2004).
14. Lysosomotropic effects were reported by Merck researchers during their studies on cathepsin K inhibitors:. Falgueyret J.-P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., Lamontagne S., Masse F., Riendeau D., Toulmond S., and Percival M.D. J. Med. Chem. 48 (2005) 7535